RESUMEN
Changes that COVID-19 induced in endocrine daily practice as well as the role of endocrine and metabolic comorbidities in COVID-19 outcomes were among the striking features of this last year. The aim of this statement is to illustrate the major characteristics of the response of European endocrinologists to the pandemic including the disclosure of the endocrine phenotype of COVID-19 with diabetes, obesity and hypovitaminosis D playing a key role in this clinical setting with its huge implication for the prevention and management of the disease. The role of the European Society of Endocrinology (ESE) as a reference point of the endocrine community during the pandemic will also be highlighted, including the refocusing of its educational and advocacy activities.
Asunto(s)
COVID-19/epidemiología , COVID-19/terapia , Endocrinólogos/organización & administración , Endocrinología/organización & administración , COVID-19/complicaciones , COVID-19/prevención & control , Redes Comunitarias/organización & administración , Redes Comunitarias/tendencias , Atención a la Salud/historia , Atención a la Salud/organización & administración , Atención a la Salud/tendencias , Enfermedades del Sistema Endocrino/diagnóstico , Enfermedades del Sistema Endocrino/epidemiología , Enfermedades del Sistema Endocrino/etiología , Enfermedades del Sistema Endocrino/terapia , Endocrinólogos/historia , Endocrinólogos/tendencias , Endocrinología/historia , Endocrinología/tendencias , Europa (Continente)/epidemiología , Historia del Siglo XXI , Humanos , Pandemias , Fenotipo , Rol del Médico , Pautas de la Práctica en Medicina/historia , Pautas de la Práctica en Medicina/organización & administración , Pautas de la Práctica en Medicina/tendencias , Sociedades Médicas/historia , Sociedades Médicas/organización & administración , Sociedades Médicas/tendencias , Telemedicina/historia , Telemedicina/organización & administración , Telemedicina/tendenciasAsunto(s)
Endocrinólogos/tendencias , Invenciones/tendencias , Pautas de la Práctica en Medicina/tendencias , Diabetes Mellitus/sangre , Diabetes Mellitus/epidemiología , Diabetes Mellitus/mortalidad , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/complicaciones , Diabetes Mellitus Tipo 1/terapia , Diabetes Mellitus Tipo 2/epidemiología , Diabetes Mellitus Tipo 2/prevención & control , Oído , Endocrinólogos/historia , Trastornos de Alimentación y de la Ingestión de Alimentos/complicaciones , Trastornos de Alimentación y de la Ingestión de Alimentos/epidemiología , Trastornos de Alimentación y de la Ingestión de Alimentos/terapia , Glucosa/análisis , Historia del Siglo XXI , Humanos , Invenciones/historia , Nitrilos/uso terapéutico , Pautas de la Práctica en Medicina/historia , Medicina de Precisión/historia , Medicina de Precisión/métodos , Medicina de Precisión/tendencias , Medicina Preventiva/tendencias , Pirazoles/uso terapéutico , Pirimidinas/uso terapéutico , Inducción de Remisión/métodos , Lágrimas/químicaRESUMEN
The world is entering an era of disaster and chaos due to coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2. Since its first emergence in December 2019 in Wuhan, China, COVID-19 has swept through Asia and propagated throughout the world to Europe and North America. As of April 13, 1,773,084 people were infected and 111,652 people had died from COVID-19 globally, and new record levels of infection are being reported every day. Based on the data that have been amassed so far, the primary risk factors for a severe disease course or even mortality from COVID-19 are underlying diseases such as diabetes and hypertension. As the global prevalence of diabetes continues to increase, patients with endocrine diseases such as diabetes mellitus and those who are on long-term corticosteroid therapy due to adrenal insufficiency or hypopituitarism are at risk for a poor prognosis of COVID-19. As endocrinologists, we would like to briefly review the current knowledge about the relationship between COVID-19 and endocrine diseases and to discuss what we can do for the safety and health of our patients with endocrine diseases in this globally threatening situation.